trial · primary record
rVSV∆G-MARV-GP
Marburg Virus Disease
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 112 |
| Primary completion | 2027-10 |
| Primary endpoint | Safety and tolerability of rVSV∆G-MARV-GP vaccination: solicited reactogenicity |
| Registry ID | NCT07425821 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:14.786Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07425821
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.